Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company ...

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

Shares of Gilead Sciences Inc. rallied 2.83% to $110.67 Friday, on what proved to be an all-around great trading session for ...

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...

(Reuters) -Shares of Gilead rose 3% after the U.S. Supreme Court on Friday upheld a federal mandate that requires health ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

Gilead Sciences Inc. closed 11.48% below its 52-week high of $119.96, which the company reached on March 10th.

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, ...

Review the current Gilead Sciences Inc (GILD:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if GILD is the best investment for you.

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...